Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hematologic Diseases 1

Interventions

pirtobrutinib 6Cyclophosphamide 6Mycophenolic Acid 5fludarabine phosphate 4fludarabine 4Rituximab 4Melphalan 4Azacitidine 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mesna 3Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Lenalidomide 2Cyclosporine 2Busulfan 2Brentuximab Vedotin 2Bone Marrow Transplantation 2Blood Specimen Collection 2Bendamustine Hydrochloride 2zanubrutinib 1ruxolitinib 1ponatinib 1pembrolizumab 1nilotinib 1idelalisib 1idecabtagene vicleucel 1cedazuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Ustekinumab × 1 year × Clear all
NCT04572815 2026-01-02

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
116 enrolled

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡